 |
McKenzie, Patti, Heather, Jeannine, Yvonne & Anne's Training Site |
|
|||||
My Educational Video on MS and MS Trials| Visitors..Plus 221,000 on MySpace |
||||||||||||||||||||||||||||||||||||||||
| Click here to go to our MySpace Page HERE'S A FEW OF OUR 3,200 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| January 2007 | ||||||||||||||||||||||||||||||||||||||||
| November 2007 | ||||||||||||||||||||||||||||||||||||||||
| April 2008 | ||||||||||||||||||||||||||||||||||||||||
| July 2008 | ||||||||||||||||||||||||||||||||||||||||
| December 2008 | ||||||||||||||||||||||||||||||||||||||||
| January 2009 | ||||||||||||||||||||||||||||||||||||||||
| February 2009 | ||||||||||||||||||||||||||||||||||||||||
| March 2009 | ||||||||||||||||||||||||||||||||||||||||
| March 2010 | ||||||||||||||||||||||||||||||||||||||||
| April 2010 | ||||||||||||||||||||||||||||||||||||||||
| May 2010 | ||||||||||||||||||||||||||||||||||||||||
| August 2010 | ||||||||||||||||||||||||||||||||||||||||
| May 2013 | ||||||||||||||||||||||||||||||||||||||||
| June 2013 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| January 2014 | ||||||||||||||||||||||||||||||||||||||||
| February 2014 | ||||||||||||||||||||||||||||||||||||||||
| March 2014 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
2/27/14
2/20/14
Overview of the Epidemiology, Diagnosis, and Disease Progression Associated With Multiple Sclerosis
The etiology of MS is unknown, but it is likely due to complex interactions between environmental and genetic factors and the immune system. The clinical manifestations and the course of MS are extremely variable, but most patients accumulate disability over time. To optimize treatment outcomes, clinicians need to be familiar with the immunopathogenesis, symptoms, and natural course of the disease, and the recently revised MS diagnostic criteria.
click to read
click to read
As Teva searches for its footing, billionaire Soros ups his stake - FiercePharma
 |
| George Soros |
Piece by piece, Teva ($TEVA) is working on its turnaround, and at least one key investor seems to think the company is headed in the right direction. Billionaire George Soros boosted his family office's stake in the Israeli company in the last quarter of 2013, adding 5.7 million shares to make the Israeli generics giant its largest holding.
As Bloomberg reports, Soros Fund Management upped its Teva holding to $373 million in Q4, according to an SEC filing. Bloomberg data lists Teva at 4% of the fund, worth $9.2 billion.
Tecfidera, the drug originally developed to treat itchy skin condition psoriasis
Tecfidera becomes second oral agent launched for MS this year
Naturally Occurring Packets Show Promise for Protecting Nerve Fibers in the Brain
click to read
2/16/14
Study Suggests Sleep Apnea May Contribute to Fatigue in Multiple Sclerosis
2/12/14
2/11/14
MULTIPLE SCLEROSIS DRUG DRAGS ON
A NEW treatment for Multiple Sclerosis approved and registered
with the Therapeutic Goods Administration last month after more than 30
years of development may not be available in Australia for the
foreseeable future.
SECONDARY PROGRESSIVE MS RESEARCH CONTINUES TO PROGRESS
Researchers continue to explore different treatment approaches for secondary progressive MS
Researchers at the Collaborative MS Research Center at the University of California
at San Francisco are working on several different treatment approaches,
as well as seeking to develop molecules that may be used as biomarkers
to help doctors predict MS progression before it occurs.
For
those MS patients who have already been diagnosed with secondary
progressive MS, the Center’s research into use of the drug Natalizumab
may offer particular hope for a definitive treatment for the disease.
2/9/14
 |
| Kris and Lisa Kirstofferson |
DESPITE
INCREASE IN MEMORY LOSS, KRIS KRISTOFFERSON MAINTAINS GREAT SENSE OF HUMOR
You can’t help but love Kris Kristofferson. Superstar singer and songwriter, Kris is also a great actor with many film credits from “A Star is Born” to “A Soldier’s Daughter Never Cries.” But Kris, who’s 77, is suffering from a form of dementia called “Puglistica.”
Read more »
2/8/14
NEW THERAPY FOR MULTIPLE SCLEROSIS LOOKS PROMISING
In their study report, Michael Pender, a professor at the University of Queensland School of Medicine, Brisbane, and colleagues describe how a patient with advanced multiple sclerosis (MS) experienced noticeable clinical improvement after receiving 6 weeks of the immunotherapy treatment.
2/7/14
 |
| MS Sufferer Barry Rudd |
Barry Rudd was just 53 when he was diagnosed with multiple sclerosis His uncommon form of the disease affects just 15 per cent of sufferers Mr Rudd was refused Sativex on the NHS while sufferers living a few miles away are being prescribed the cannabis spray The drug hasn't been assessed by the National Institute for Health and Clinical Excellence – meaning funding decisions are not uniform across NHS
Read more »
2/1/14
UPDATED: Corks are a-popping at Teva with FDA nod for its new Copaxone formula
UPDATED: Corks are a-popping at Teva with FDA nod for its new Copaxone formula
Teva Pharmaceutical Industries hit the finish line in its long race
to develop a longer-acting formulation of its multiple sclerosis
treatment Copaxone. Tuesday evening, Teva ($TEVA) said the FDA had approved the three-times-weekly formula, and not a moment too soon. The Israel-based
drugmaker now has till mid-May to convert as many patients as possible
to the latest and greatest version, before the original drug's patent
expires.
Teva executives predict that 45% of current Copaxone patients will convert to the long-acting formulation. It needs as many conversions as it can get; the original is Teva's biggest seller, with about 20% of its revenue and 50% of its profits. In 2012, the drug brought in $3 billion in the U.S. alone.
There's no word yet on pricing for the longer-acting dose, and Teva's full-year 2013 figures aren't yet out, so there's no way to guesstimate how much a 45% conversion would be worth, dollar-wise. We'll leave that number crunching to the analysts; their consensus estimates are for $4.2 billion in global Copaxone sales for 2013.
Suffice it to say that Teva should be thrilled if its conversions keep ahead of generic erosion once copycat rivals hit the market. With patent protection till 2030 on this model, it could pay off for many years to come. But that's not a given; new formula or old, Copaxone does face competition from other brands, including the Novartis ($NVS) pill Gilenya, Sanofi's ($SNY) Aubagio, and Biogen Idec's ($BIIB) new-and-hot Tecfidera.
The new formula is shipping immediately and will be available to patients "within days," the company said in a statement. Teva has staffed up at its patient support center--Shared Solutions--to help current patients move to the thrice-weekly formulation. That means help navigating insurance coverage, finding the right pharmacy, and for some, financial assistance. Patients can even call the hotline directly to ask to switch. Of course they can also call their doctors, and DTC ads will no doubt soon urge them to do so. And Teva reps have been gearing up for some time to spread the word to physicians.
The company thought it would have 18 more months to persuade patients to make the Copaxone switch, but a U.S. appeals court last year invalidated a patent that expired next November. Now, the fuse runs out in May. Teva hasn't given up on the original formula, though. Last week, the company asked the U.S. Supreme Court to take up its patent case. And it's still arguing for stepped-up FDA scrutiny for any would-be Copaxone copycats. Meanwhile, Teva continues to cut costs and lay off workers in a worldwide restructuring designed to save $2 billion.
- see the Teva release
Special Reports: Top 10 Drug Patent Losses of 2014 - Copaxone | Top 10 Generics Makers by 2012 Revenue - Teva
Related Articles:
Teva appeals to Supreme Court for help thwarting Copaxone rivals
Teva braces for a $550M hit from Copaxone generics
CHMP recommendation adds to Teva's financial turmoil
Teva plots 5,000 more job cuts in $2B savings drive
Teva executives predict that 45% of current Copaxone patients will convert to the long-acting formulation. It needs as many conversions as it can get; the original is Teva's biggest seller, with about 20% of its revenue and 50% of its profits. In 2012, the drug brought in $3 billion in the U.S. alone.
There's no word yet on pricing for the longer-acting dose, and Teva's full-year 2013 figures aren't yet out, so there's no way to guesstimate how much a 45% conversion would be worth, dollar-wise. We'll leave that number crunching to the analysts; their consensus estimates are for $4.2 billion in global Copaxone sales for 2013.
Suffice it to say that Teva should be thrilled if its conversions keep ahead of generic erosion once copycat rivals hit the market. With patent protection till 2030 on this model, it could pay off for many years to come. But that's not a given; new formula or old, Copaxone does face competition from other brands, including the Novartis ($NVS) pill Gilenya, Sanofi's ($SNY) Aubagio, and Biogen Idec's ($BIIB) new-and-hot Tecfidera.
The new formula is shipping immediately and will be available to patients "within days," the company said in a statement. Teva has staffed up at its patient support center--Shared Solutions--to help current patients move to the thrice-weekly formulation. That means help navigating insurance coverage, finding the right pharmacy, and for some, financial assistance. Patients can even call the hotline directly to ask to switch. Of course they can also call their doctors, and DTC ads will no doubt soon urge them to do so. And Teva reps have been gearing up for some time to spread the word to physicians.
The company thought it would have 18 more months to persuade patients to make the Copaxone switch, but a U.S. appeals court last year invalidated a patent that expired next November. Now, the fuse runs out in May. Teva hasn't given up on the original formula, though. Last week, the company asked the U.S. Supreme Court to take up its patent case. And it's still arguing for stepped-up FDA scrutiny for any would-be Copaxone copycats. Meanwhile, Teva continues to cut costs and lay off workers in a worldwide restructuring designed to save $2 billion.
- see the Teva release
Special Reports: Top 10 Drug Patent Losses of 2014 - Copaxone | Top 10 Generics Makers by 2012 Revenue - Teva
Related Articles:
Teva appeals to Supreme Court for help thwarting Copaxone rivals
Teva braces for a $550M hit from Copaxone generics
CHMP recommendation adds to Teva's financial turmoil
Teva plots 5,000 more job cuts in $2B savings drive
Teva stands by its MS pill after yet another setback
Teva stands by its MS pill after yet another setback
European regulators recommended against Teva Pharmaceutical's ($TEVA) laquinimod, marring the Israeli company's odds of crossing the finish line with its once-promising multiple sclerosis treatment, a drug it hopes can dull the blow of the soon-to-go-generic Copaxone.
The European Medicines Agency's Committee for Medicinal Products for Human Use took issue with the drug's risk-benefit profile, pointing to safety risks that popped up in animal studies and weren't dispelled by human trials. Long-term exposure to the drug was tied to a higher occurrence of cancers and some dangers for pregnant women, CHMP said, and regulators weren't convinced by Teva's proposed safety measures. On the efficacy side, despite laquinimod's ability to slow the progression of MS-related disability, regulators were unimpressed with the drug's effect on relapses.
But Teva and partner Active Biotech aren't giving up, requesting a re-examination and planning to "liaise closely with the EMA" in hopes of salvaging laquinimod's future in Europe.
Read more »
Read more »
Read more »
